more

Alder BioPharmaceuticals, Inc. (ALDR)

(Delayed Data from NSDQ)

$12.28 USD

+0.04 (0.33%)

Updated May 3, 2019 04:00 PM ET

After-Market: $12.28 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy

by Zacks Equity Research Published on October 15,2019

Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ALDRPositive Net Change

Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap

by Zacks Equity Research Published on September 27,2019

Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap

retail

Use Rising P/E Strategy to Grab 5 Winning Stocks

by Sanghamitra Saha Published on September 26,2019

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

earnings

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

by Zacks Equity Research Published on September 18,2019

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

biotechs

Company News For Sep 17, 2019

by Zacks Equity Research Published on September 17,2019

Companies in the news are: ALDR, GM, NEWR, SEMG

Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

by Zacks Equity Research Published on September 17,2019

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

biotechs

Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on September 10,2019

Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

ALDRPositive Net Change

medical

MyoKardia Begins Dosing in Phase I Study on Heart Candidate

by Zacks Equity Research Published on August 22,2019

MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.

biotechs

NuCana Stops Patient Enrollment in Pancreatic Cancer Study

by Zacks Equity Research Published on August 21,2019

NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.

What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?

by Zacks Equity Research Published on August 16,2019

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.

biotechs

Alder Biopharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on July 19,2019

Alder Biopharmaceuticals, Inc. (ALDR) has been struggling lately, but the selling pressure may be coming to an end soon.

ALDRPositive Net Change

medical

All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Buy

by Zacks Equity Research Published on July 03,2019

Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ALDRPositive Net Change

Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

by Zacks Equity Research Published on May 06,2019

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research Published on February 12,2019

Molina Healthcare's (MOH) fourth-quarter earnings trump estimates on the back of lower costs and higher premium revenues.

medical

Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y

by Zacks Equity Research Published on February 08,2019

Ensign Group's (ENSG) fourth-quarter earnings rise on the back of solid segmental growth.

medical

MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y

by Zacks Equity Research Published on February 08,2019

Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.

medical

Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?

by Zacks Equity Research Published on February 07,2019

Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.

medical

Alder BioPharmaceuticals (ALDR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on February 06,2019

Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.